Buntanetap mesylate (formerly ANVS401/PD-01) is an oral small molecule drug being developed for the treatment of Alzheimer's disease and Parkinson's disease. This Phase 3 clinical trial (NCT06709014) is evaluating the safety and efficacy of Buntanetap in participants with early Alzheimer's disease[1].
The trial is sponsored by Annovis Bio Inc. and represents a significant advancement in developing disease-modifying therapies for neurodegenerative conditions. Buntanetap targets multiple pathological pathways implicated in Alzheimer's disease pathogenesis, including amyloid processing, tau phosphorylation, neuroinflammation, and synaptic dysfunction[2].
| Parameter | Value |
|---|---|
| NCT Number | NCT06709014 |
| Phase | Phase 3 |
| Status | RECRUITING |
| Sponsor | Annovis Bio Inc. |
| Enrollment | 760 participants (estimated) |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | February 4, 2025 |
| Completion Date | June 1, 2028 |
| Last Updated | January 30, 2026 |
Buntanetap represents a novel approach to Alzheimer's disease therapy by targeting multiple pathological mechanisms simultaneously[3]:
Alpha-Synuclein Aggregation Inhibition: While primarily associated with Parkinson's disease, alpha-synuclein pathology is increasingly recognized in AD, particularly in the subtype of AD with Lewy body co-pathology.
Amyloid-Beta Processing: Buntanetap affects APP (amyloid precursor protein) processing to reduce amyloid-beta production through modulation of beta-secretase (BACE1) activity.
Tau Phosphorylation: The drug reduces tau hyperphosphorylation through inhibition of several kinases, potentially slowing neurofibrillary tangle formation.
Synaptic Protection: Buntanetap protects synaptic function by maintaining neurotransmitter release and synaptic plasticity[4].
Mitochondrial Function: The drug supports mitochondrial integrity and function, addressing the energy deficit observed in AD brains[5].
Buntanetap acts as a small molecule inhibitor that:
Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans alone[6]. The disease is characterized by:
Pathologically, AD is characterized by:
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis[7]. It proposes that:
However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches that address multiple pathological features simultaneously.
Current FDA-approved treatments for AD include:
These treatments provide symptomatic benefit but do not halt disease progression. The field has increasingly focused on disease-modifying therapies that target underlying pathological mechanisms.
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial[8]. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations.
| Arm | Description | Duration |
|---|---|---|
| Buntanetap Low Dose | Oral administration | 6 months / 18 months |
| Buntanetap High Dose | Oral administration | 6 months / 18 months |
| Placebo | Matching oral tablet | 6 months / 18 months |
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13): A validated cognitive assessment measuring memory, language, praxis, and executive function.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL): Measures functional abilities including shopping, cooking, managing finances, and medication use.
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease[9]. The outcomes of this study may:
Advance therapeutic options: Successful results could lead to new treatment paradigms for patients with early AD
Validate multi-target approach: Demonstrating efficacy would validate targeting multiple pathological pathways simultaneously
Improve understanding: The trial contributes to our knowledge of disease mechanisms through biomarker investigations
Inform precision medicine: Results may help identify patient subgroups who benefit most from Buntanetap therapy
While originally developed for Parkinson's disease, Buntanetap's mechanism is highly relevant to AD:
The trial is being conducted at multiple centers worldwide, including:
Novel therapeutic approaches for neurodegenerative diseases (2024). 2024. ↩︎
Mechanism-driven clinical trials in neurodegeneration (2024). 2024. ↩︎
Buntanetap (ANVS401) mechanism of action in neurodegeneration. 2024. ↩︎
Mitochondrial dysfunction in Alzheimer's disease pathogenesis. 2024. ↩︎
Alzheimer's disease: global burden and opportunities for intervention (2023). 2023. ↩︎
Amyloid cascade hypothesis: time for a reappraisal (2023). 2023. ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎